Abstract
Background:
The MADS-box transcription factor myocyte enhancer factor 2C (MEF2C) is required for the cardiac development and postnatal adaptation and in mice-targeted disruption of the MEF2C gene results in dilated cardiomyopathy (DCM). However, in humans, the association of MEF2C variation with DCM remains to be investigated.
Methods:
The coding regions and splicing boundaries of the MEF2C gene were sequenced in 172 unrelated patients with idiopathic DCM. The available close relatives of the index patient harboring an identified MEF2C mutation and 300 unrelated, ethnically matched healthy individuals used as controls were genotyped for MEF2C. The functional effect of the mutant MEF2C protein was characterized in contrast to its wild-type counterpart by using a dual-luciferase reporter assay system.
Results:
A novel heterozygous MEF2C mutation, p.Y157X, was detected in an index patient with adult-onset DCM. Genetic screen of the mutation carrier’s family members revealed that the mutation co-segregated with DCM, which was transmitted as an autosomal dominant trait with complete penetrance. The non-sense mutation was absent in 300 control individuals. Functional analyses unveiled that the mutant MEF2C protein had no transcriptional activity. Furthermore, the mutation abolished the synergistic transactivation between MEF2C and GATA4 as well as HAND1, two other transcription factors that have been associated with DCM.
Conclusions:
This study indicates MEF2C as a new gene responsible for human DCM, which provides novel insight into the mechanism underpinning DCM, suggesting potential implications for development of innovative prophylactic and therapeutic strategies for DCM, the most prevalent form of primary myocardial disease.
Acknowledgments
We are really grateful to the study participants for their devotion to the investigation.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This work was partially supported by grants from the National Natural Science Fund of China (81470372 and 81370400); the Experimental Animal Program of Shanghai, China (16140901602); the key program for Basic Research of Shanghai, China (14JC1405500); the Natural Science Fund of Shanghai, China (14ZR1438000 and 15ZR1438100); and the key project of Shanghai Chest Hospital, China (2014YZDH10102).
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet 2017;390:400–1410.1016/S0140-6736(16)31713-5Search in Google Scholar
2. Cho KW, Lee J, Kim Y. Genetic variations leading to familial dilated cardiomyopathy. Mol Cells 2016;39:722–7.Search in Google Scholar
3. McNally EM, Golbus JR, Puckelwartz MJ. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest 2013;123:19–26.10.1172/JCI62862Search in Google Scholar PubMed PubMed Central
4. Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 2015;36:1123–35a.10.1093/eurheartj/ehu301Search in Google Scholar PubMed
5. Reinstein E, Orvin K, Tayeb-Fligelman E, Stiebel-Kalish H, Tzur S, Pimienta AL, et al. Mutations in TAX1BP3 cause dilated cardiomyopathy with septo-optic dysplasia. Hum Mutat 2015;36:439–42.10.1002/humu.22759Search in Google Scholar PubMed
6. Liaquat A, Shauket U, Ahmad W, Javed Q. The tumor necrosis factor-α -238G/A and IL-6 -572G/C gene polymorphisms and the risk of idiopathic dilated cardiomyopathy: a meta-analysis of 25 studies including 9493 cases and 13,971 controls. Clin Chem Lab Med 2015;53:307–18.10.1515/cclm-2014-0502Search in Google Scholar PubMed
7. Akinrinade O, Ollila L, Vattulainen S, Tallila J, Gentile M, Salmenperä P, et al. Genetics and genotype-phenotype correlations in Finnish patients with dilated cardiomyopathy. Eur Heart J 2015;36:2327–37.10.1093/eurheartj/ehv253Search in Google Scholar PubMed PubMed Central
8. Yuan F, Qiu XB, Li RG, Qu XK, Wang J, Xu YJ, et al. A novel NKX2-5 loss-of-function mutation predisposes to familial dilated cardiomyopathy and arrhythmias. Int J Mol Med 2015;35:478–86.10.3892/ijmm.2014.2029Search in Google Scholar PubMed
9. Beqqali A, Bollen IA, Rasmussen TB, van den Hoogenhof MM, van Deutekom HW, Schafer S, et al. A mutation in the glutamate-rich region of RNA-binding motif protein 20 causes dilated cardiomyopathy through missplicing of titin and impaired Frank-Starling mechanism. Cardiovasc Res 2016;112:452–63.10.1093/cvr/cvw192Search in Google Scholar PubMed
10. Reinstein E, Gutierrez-Fernandez A, Tzur S, Bormans C, Marcu S, Tayeb-Fligelman E, et al. Congenital dilated cardiomyopathy caused by biallelic mutations in Filamin C. Eur J Hum Genet 2016;24:1792–6.10.1038/ejhg.2016.110Search in Google Scholar PubMed PubMed Central
11. Long PA, Zimmermann MT, Kim M, Evans JM, Xu X, Olson TM. De novo RRAGC mutation activates mTORC1 signaling in syndromic fetal dilated cardiomyopathy. Hum Genet 2016;135:909–17.10.1007/s00439-016-1685-3Search in Google Scholar PubMed PubMed Central
12. Cuenca S, Ruiz-Cano MJ, Gimeno-Blanes JR, Jurado A, Salas C, Gomez-Diaz I, et al. Inherited Cardiac Diseases Program of the Spanish Cardiovascular Research Network (Red Investigación Cardiovascular). Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. J Heart Lung Transplant 2016;35:625–35.10.1016/j.healun.2015.12.014Search in Google Scholar PubMed
13. Al-Hassnan ZN, Shinwari ZM, Wakil SM, Tulbah S, Mohammed S, Rahbeeni Z, et al. A substitution mutation in cardiac ubiquitin ligase, FBXO32, is associated with an autosomal recessive form of dilated cardiomyopathy. BMC Med Genet 2016;17:3.10.1186/s12881-016-0267-5Search in Google Scholar PubMed PubMed Central
14. Al-Yacoub N, Shaheen R, Awad SM, Kunhi M, Dzimiri N, Nguyen HC, et al. FBXO32, encoding a member of the SCF complex, is mutated in dilated cardiomyopathy. Genome Biol 2016;17:2.10.1186/s13059-015-0861-4Search in Google Scholar PubMed PubMed Central
15. Sabater-Molina M, Navarro M, García-Molina Sáez E, Garrido I, Pascual-Figal D, González Carrillo J, et al. Mutation in JPH2 cause dilated cardiomyopathy. Clin Genet 2016;90:468–9.10.1111/cge.12825Search in Google Scholar PubMed
16. Brodehl A, Dieding M, Biere N, Unger A, Klauke B, Walhorn V, et al. Functional characterization of the novel DES mutation p.L136P associated with dilated cardiomyopathy reveals a dominant filament assembly defect. J Mol Cell Cardiol 2016;91:207–14.10.1016/j.yjmcc.2015.12.015Search in Google Scholar PubMed
17. Zhao CM, Sun B, Song HM, Wang J, Xu WJ, Jiang JF, et al. TBX20 loss-of-function mutation associated with familial dilated cardiomyopathy. Clin Chem Lab Med 2016;54:325–32.10.1515/cclm-2015-0328Search in Google Scholar PubMed
18. Zhou YM, Dai XY, Qiu XB, Yuan F, Li RG, Xu YJ, et al. HAND1 loss-of-function mutation associated with familial dilated cardiomyopathy. Clin Chem Lab Med 2016;54:1161–7.10.1515/cclm-2015-0766Search in Google Scholar PubMed
19. Toro R, Pérez-Serra A, Campuzano O, Moncayo-Arlandi J, Allegue C, Iglesias A, et al. Familial dilated cardiomyopathy caused by a novel frameshift in the BAG3 gene. PLoS One 2016;11:e0158730.10.1371/journal.pone.0158730Search in Google Scholar PubMed PubMed Central
20. Dalin MG, Engström PG, Ivarsson EG, Unneberg P, Light S, Schaufelberger M, et al. Massive parallel sequencing questions the pathogenic role of missense variants in dilated cardiomyopathy. Int J Cardiol 2017;228:742–8.10.1016/j.ijcard.2016.11.066Search in Google Scholar PubMed
21. Esslinger U, Garnier S, Korniat A, Proust C, Kararigas G, Müller-Nurasyid M, et al. Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy. PLoS One 2017;12:e0172995.10.1371/journal.pone.0172995Search in Google Scholar PubMed PubMed Central
22. Rafiq MA, Chaudhry A, Care M, Spears DA, Morel CF, Hamilton RM. Whole exome sequencing identified 1 base pair novel deletion in BCL2-associated athanogene 3 (BAG3) gene associated with severe dilated cardiomyopathy (DCM) requiring heart transplant in multiple family members. Am J Med Genet A 2017;173:699–705.10.1002/ajmg.a.38087Search in Google Scholar
23. Qiu XB, Qu XK, Li RG, Liu H, Xu YJ, Zhang M, et al. CASZ1 loss-of-function mutation contributes to familial dilated cardiomyopathy. Clin Chem Lab Med 2017;55:1417–25.10.1515/cclm-2016-0612Search in Google Scholar
24. Long PA, Theis JL, Shih YH, Maleszewski JJ, Abell Aleff PC, Evans JM, et al. Recessive TAF1A mutations reveal ribosomopathy in siblings with end-stage pediatric dilated cardiomyopathy. Hum Mol Genet 2017;26:2874–81.10.1093/hmg/ddx169Search in Google Scholar
25. Janin A, N’Guyen K, Habib G, Dauphin C, Chanavat V, Bouvagnet P, et al. Truncating mutations on myofibrillar myopathies causing genes as prevalent molecular explanations on patients with dilated cardiomyopathy. Clin Genet 2017. doi: 10.1111/cge.13043.10.1111/cge.13043Search in Google Scholar
26. Dal Ferro M, Stolfo D, Altinier A, Gigli M, Perrieri M, Ramani F, et al. Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy. Heart 2017. doi: 10.1136/heartjnl-2016-311017.10.1136/heartjnl-2016-311017Search in Google Scholar
27. Zhou C, Li C, Zhou B, Sun H, Koullourou V, Holt I, et al. Novel nesprin-1 mutations associated with dilated cardiomyopathy cause nuclear envelope disruption and defects in myogenesis. Hum Mol Genet 2017;26:2258–76.10.1093/hmg/ddx116Search in Google Scholar
28. Fatkin D, Huttner IG. Titin-truncating mutations in dilated cardiomyopathy: the long and short of it. Curr Opin Cardiol 2017. doi: 10.1097/HCO.0000000000000382.10.1097/HCO.0000000000000382Search in Google Scholar
29. Akazawa H, Komuro I. Cardiac transcription factor Csx/Nkx2-5: Its role in cardiac development and diseases. Pharmacol Ther 2005;107:252–68.10.1016/j.pharmthera.2005.03.005Search in Google Scholar
30. Srivastava D. HAND proteins: molecular mediators of cardiac development and congenital heart disease. Trends Cardiovasc Med 1999;9:11–8.10.1016/S1050-1738(98)00033-4Search in Google Scholar
31. Pikkarainen S, Tokola H, Kerkelä R, Ruskoaho H. GATA transcription factors in the developing and adult heart. Cardiovasc Res 2004;63:196–207.10.1016/j.cardiores.2004.03.025Search in Google Scholar PubMed
32. Greulich F, Rudat C, Kispert A. Mechanisms of T-box gene function in the developing heart. Cardiovasc Res 2011;91:212–22.10.1093/cvr/cvr112Search in Google Scholar PubMed
33. Oka T, Xu J, Molkentin JD. Re-employment of developmental transcription factors in adult heart disease. Semin Cell Dev Biol 2007;18:117–31.10.1016/j.semcdb.2006.11.012Search in Google Scholar PubMed PubMed Central
34. Li YJ, Yang YQ. An update on the molecular diagnosis of congenital heart disease: focus on loss-of-function mutations. Expert Rev Mol Diagn 2017;17:393–401.10.1080/14737159.2017.1300062Search in Google Scholar PubMed
35. Li J, Liu WD, Yang ZL, Yuan F, Xu L, Li RG, et al. Prevalence and spectrum of GATA4 mutations associated with sporadic dilated cardiomyopathy. Gene 2014;548:174–81.10.1016/j.gene.2014.07.022Search in Google Scholar PubMed
36. Zhang XL, Dai N, Tang K, Chen YQ, Chen W, Wang J, et al. GATA5 loss-of-function mutation in familial dilated cardiomyopathy. Int J Mol Med 2015;35:763–70.10.3892/ijmm.2014.2050Search in Google Scholar PubMed
37. Xu L, Zhao L, Yuan F, Jiang WF, Liu H, Li RG, et al. GATA6 loss-of-function mutations contribute to familial dilated cardiomyopathy. Int J Mol Med 2014;34:1315–22.10.3892/ijmm.2014.1896Search in Google Scholar PubMed
38. Zhang XL, Qiu XB, Yuan F, Wang J, Zhao CM, Li RG, et al. TBX5 loss-of-function mutation contributes to familial dilated cardiomyopathy. Biochem Biophys Res Commun 2015;459:166–71.10.1016/j.bbrc.2015.02.094Search in Google Scholar PubMed
39. Edmondson DG, Lyons GE, Martin JF, Olson EN. Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouseembryogenesis. Development 1994;120:1251–63.10.1242/dev.120.5.1251Search in Google Scholar PubMed
40. Iida K, Hidaka K, Takeuchi M, Nakayama M, Yutani C, Mukai T, et al. Expression of MEF2 genes during human cardiac development. Tohoku J Exp Med 1999;187:15–23.10.1620/tjem.187.15Search in Google Scholar PubMed
41. Lin Q, Schwarz J, Bucana C, Olson EN. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 1997;276:1404–7.10.1126/science.276.5317.1404Search in Google Scholar PubMed PubMed Central
42. Kolodziejczyk SM, Wang L, Balazsi K, DeRepentigny Y, Kothary R, Megeney LA. MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium. Curr Biol 1999;9:1203–6.10.1016/S0960-9822(00)80027-5Search in Google Scholar
43. Xu J, Gong NL, Bodi I, Aronow BJ, Backx PH, Molkentin JD. Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice. J Biol Chem 2006;281:9152–62.10.1074/jbc.M510217200Search in Google Scholar PubMed
44. Naya FJ, Black BL, Wu H, Bassel-Duby R, Richardson JA, Hill JA, et al. Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. Nat Med 2002;8:1303–9.10.1038/nm789Search in Google Scholar PubMed
45. Elliott P, O’Mahony C, Syrris P, Evans A, Rivera Sorensen C, Sheppard MN, et al. Prevalence of desmosomal protein gene mutations in patients with dilated cardiomyopathy. Circ Cardiovasc Genet 2010;3:314–22.10.1161/CIRCGENETICS.110.937805Search in Google Scholar PubMed
46. Dong C, Yang XZ, Zhang CY, Liu YY, Zhou RB, Cheng QD, et al. Myocyte enhancer factor 2C and its directly-interacting proteins: a review. Prog Biophys Mol Biol 2017;126:22–30.10.1016/j.pbiomolbio.2017.02.002Search in Google Scholar PubMed
47. Morin S, Charron F, Robitaille L, Nemer M. GATA-dependent recruitment of MEF2 proteins to target promoters. EMBO J 2000;19:2046–55.10.1093/emboj/19.9.2046Search in Google Scholar PubMed PubMed Central
48. Zang MX, Li Y, Xue LX, Jia HT, Jing H. Cooperative activation of atrial naturetic peptide promoter by dHAND and MEF2C. J Cell Biochem 2004;93:1255–66.10.1002/jcb.20225Search in Google Scholar PubMed
49. Ghosh TK, Song FF, Packham EA, Buxton S, Robinson TE, Ronksley J, et al. Physical interaction between TBX5 and MEF2C is required for early heart development. Mol Cell Biol 2009;29:2205–18.10.1128/MCB.01923-08Search in Google Scholar PubMed PubMed Central
50. Morin S, Pozzulo G, Robitaille L, Cross J, Nemer M. MEF2-dependent recruitment of the HAND1 transcription factor results in synergistic activation of target promoters. J Biol Chem 2005;280:32272–8.10.1074/jbc.M507640200Search in Google Scholar PubMed
51. Lilly B, Zhao B, Ranganayakulu G, Paterson BM, Schulz RA, Olson EN. Requirement of MADS domain transcription factor D-MEF2 for muscle formation in Drosophila. Science 1995;267:688–93.10.1126/science.7839146Search in Google Scholar PubMed
52. Hinits Y, Pan L, Walker C, Dowd J, Moens CB, Hughes SM. Zebrafish Mef2ca and Mef2cb are essential for both first and second heart field cardiomyocyte differentiation. Dev Biol 2012;369:199–210.10.1016/j.ydbio.2012.06.019Search in Google Scholar PubMed PubMed Central
53. Barnes RM, Harris IS, Jaehnig EJ, Sauls K, Sinha T, Rojas A, et al. MEF2C regulates outflow tract alignment and transcriptional control of Tdgf1. Development 2016;143:774–9.10.1242/dev.126383Search in Google Scholar PubMed PubMed Central
54. Pereira AH, Clemente CF, Cardoso AC, Theizen TH, Rocco SA, Judice CC, et al. MEF2C silencing attenuates load-induced left ventricular hypertrophy by modulating mTOR/S6K pathway in mice. PLoS One 2009;4:e8472.10.1371/journal.pone.0008472Search in Google Scholar PubMed PubMed Central
55. Alonso-Montes C, Naves-Diaz M, Fernandez-Martin JL, Rodriguez-Reguero J, Moris C, Coto E, et al. New polymorphisms in human MEF2C gene as potential modifier of hypertrophic cardiomyopathy. Mol Biol Rep 2012;39:8777–85.10.1007/s11033-012-1740-7Search in Google Scholar PubMed
56. Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010; 142:375–86.10.1016/j.cell.2010.07.002Search in Google Scholar PubMed PubMed Central
57. Song K, Nam YJ, Luo X, Qi X, Tan W, Huang GN, et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 2012;485:599–604.10.1038/nature11139Search in Google Scholar PubMed PubMed Central
58. Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, Liu L, et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012;485:593–8.10.1038/nature11044Search in Google Scholar PubMed PubMed Central
59. Kodo K, Nishizawa T, Furutani M, Arai S, Ishihara K, Oda M, et al. Genetic analysis of essential cardiac transcription factors in 256 patients with non-syndromic congenital heart defects. Circ J 2012;76:1703–11.10.1253/circj.CJ-11-1389Search in Google Scholar PubMed
60. Rocha H, Sampaio M, Rocha R, Fernandes S, Leão M. MEF2C haploinsufficiency syndrome: Report of a new MEF2C mutation and review. Eur J Med Genet 2016;59:478–82.10.1016/j.ejmg.2016.05.017Search in Google Scholar PubMed
61. Yu H, Xu JH, Song HM, Zhao L, Xu WJ, Wang J, et al. Mutational spectrum of the NKX2-5 gene in patients with lone atrial fibrillation. Int J Med Sci 2014;11:554–63.10.7150/ijms.8407Search in Google Scholar PubMed PubMed Central
Supplemental Material:
The online version of this article offers supplementary material (https://doi.org/10.1515/cclm-2017-0461).
©2018 Walter de Gruyter GmbH, Berlin/Boston
